Innovate Pharmaceuticals appoints Deloitte as advisor in licensing deal for first truly liquid aspirin
Innovate Pharmaceuticals, a privately held UK company, is seeking a global partner to license and market its liquid aspirin drug.
Innovate specialises in ‘excipient engineering’ and has developed the world’s first ‘shelf stable’ truly liquid aspirin. Innovate’s liquid aspirin enables faster and more complete absorption resulting in potentially drastic reductions in gastric side effects, the latter being the chief disadvantage of existing preparations of aspirin. The product’s shelf stability and durability improves ease and convenience of use.
After an intensive five year program with Croda International Plc, Innovate Pharmaceuticals has achieved its goal of producing a stable preparation of liquid aspirin. Other versions of so-called soluble aspirin are generally unstable suspensions containing particulate matter, which cause gastric irritation. Innovate’s product is a true solution devoid of any particulate matter which is known to cause gastric irritation.
Innovate’s CEO, Simon Cohen says: ‘We are enormously proud of this ground-breaking work and look forward to the product coming to market. A significant proportion of potential aspirin users cannot tolerate its gastric side effects. Liquid aspirin will become the natural choice for this group and our product, as the only truly stable liquid aspirin, when commercialized, represents a USD 500m-a-year business to any potential licensing partner, with only a modest 15-20% of the addressable market.’
Innovate’s CMO, practicing consultant physician Dr Jimmy Stuart says: ‘this is the realisation of five years of very hard work. What we have developed some would regard as the ‘holy grail’ of Aspirin research. We want to get this product to the market as soon as possible so that many millions of patients can experience its benefits.’
Deloitte has been engaged to secure a strategic partnership to commercialise the opportunity. David Jones, a Partner at Deloitte said ‘We are excited to work with Innovate Pharmaceuticals and assist in out-licensing their product.’
For further information please contact:
Chief Executive Officer
Tel: +4478 6654 4584
Assistant Director | Corporate Finance | Healthcare & Lifesciences
Athene Place, 66 Shoe Lane, London, EC4A 3BQ, United Kingdom
Tel: +44 (0)20 7303 7820 | Fax: +44 (0)20 7007 2354 | Mobile: +44 (0)7500 954 151
firstname.lastname@example.org | http://www2.deloitte.com/uk/en/services/corporate-finance.html
'Innovate Is a Medical Innovations Company That Re-Engineers Pharmaceutical Platforms and Breathes New Patent Life into Existing Pharmaceuticals'
Aspirin’s main limiting factor is its propensity for causing gastro-intestinal side effects, principally stomach ulcers which may bleed or perforate. Removing or even reducing these factors will ‘tip the balance’ in favour of benefit over risk. This ‘tipping point’ will unlock Aspirin’s true potential.
“The idea of a liquid form of aspirin is intriguing – anything that could reduce the potential side effects of aspirin could help to boost its usefulness in preventing diseases such as cancer.”
(Dr Julie Sharp, head of health information at Cancer Research UK).